JP4897484B2 - Ｃ型肝炎ウイルスを治療するためのシクロアルキル複素環化合物 - Google Patents

Ｃ型肝炎ウイルスを治療するためのシクロアルキル複素環化合物 Download PDF

Info

Publication number
JP4897484B2
JP4897484B2 JP2006526121A JP2006526121A JP4897484B2 JP 4897484 B2 JP4897484 B2 JP 4897484B2 JP 2006526121 A JP2006526121 A JP 2006526121A JP 2006526121 A JP2006526121 A JP 2006526121A JP 4897484 B2 JP4897484 B2 JP 4897484B2
Authority
JP
Japan
Prior art keywords
mmol
cyclohexyl
phenyl
give
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006526121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505114A (ja
JP2007505114A5 (enExample
Inventor
ピーター ダブリュー グルンツ
ブレント ディー ドゥーティー
スコット ダブリュー マーティン
ジェフリー ローマイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2007505114A publication Critical patent/JP2007505114A/ja
Publication of JP2007505114A5 publication Critical patent/JP2007505114A5/ja
Application granted granted Critical
Publication of JP4897484B2 publication Critical patent/JP4897484B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2006526121A 2003-09-11 2004-08-24 Ｃ型肝炎ウイルスを治療するためのシクロアルキル複素環化合物 Expired - Fee Related JP4897484B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50206703P 2003-09-11 2003-09-11
US60/502,067 2003-09-11
PCT/US2004/027533 WO2005034850A2 (en) 2003-09-11 2004-08-24 Cycloalkyl heterocycles for treating hepatitis c virus

Publications (3)

Publication Number Publication Date
JP2007505114A JP2007505114A (ja) 2007-03-08
JP2007505114A5 JP2007505114A5 (enExample) 2007-10-11
JP4897484B2 true JP4897484B2 (ja) 2012-03-14

Family

ID=34434839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526121A Expired - Fee Related JP4897484B2 (ja) 2003-09-11 2004-08-24 Ｃ型肝炎ウイルスを治療するためのシクロアルキル複素環化合物

Country Status (7)

Country Link
US (1) US7112601B2 (enExample)
EP (1) EP1663105B1 (enExample)
JP (1) JP4897484B2 (enExample)
AT (1) ATE498398T1 (enExample)
DE (1) DE602004031435D1 (enExample)
ES (1) ES2358904T3 (enExample)
WO (1) WO2005034850A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT502258B1 (de) * 2005-07-22 2007-09-15 Univ Wien Cox-i-inhibitorverbindungen
WO2007019397A2 (en) * 2005-08-05 2007-02-15 Genelabs Technologies, Inc. 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
BRPI0716060A2 (pt) * 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
WO2009028418A1 (ja) 2007-08-24 2009-03-05 Sapporo Medical University シクロスポリンａ結合タンパク質
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024725A1 (en) * 1998-10-26 2000-05-04 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
WO2002004425A2 (en) * 2000-07-06 2002-01-17 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2003000254A1 (fr) * 2001-06-26 2003-01-03 Japan Tobacco Inc. Composes cycliques condenses et utilisations medicales de ceux-ci
WO2003026587A2 (en) * 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ322674A (en) * 1995-10-17 1999-08-30 Searle & Co Method of detecting cyclooxygenase-2
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
CN1324250A (zh) 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
WO2000018231A1 (en) 1998-09-25 2000-04-06 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
PL395097A1 (pl) 2001-06-11 2011-10-10 Vertex Pharmaceuticals (Canada) Incorporated Sposób wytwarzania związku o wzorze A stanowiącego pochodną tiofenu
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024725A1 (en) * 1998-10-26 2000-05-04 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
WO2002004425A2 (en) * 2000-07-06 2002-01-17 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2003000254A1 (fr) * 2001-06-26 2003-01-03 Japan Tobacco Inc. Composes cycliques condenses et utilisations medicales de ceux-ci
WO2003026587A2 (en) * 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus

Also Published As

Publication number Publication date
EP1663105A4 (en) 2009-04-15
US20050075376A1 (en) 2005-04-07
DE602004031435D1 (de) 2011-03-31
EP1663105B1 (en) 2011-02-16
JP2007505114A (ja) 2007-03-08
WO2005034850A3 (en) 2006-03-16
WO2005034850A2 (en) 2005-04-21
ATE498398T1 (de) 2011-03-15
EP1663105A2 (en) 2006-06-07
US7112601B2 (en) 2006-09-26
ES2358904T3 (es) 2011-05-16

Similar Documents

Publication Publication Date Title
JP4897484B2 (ja) Ｃ型肝炎ウイルスを治療するためのシクロアルキル複素環化合物
CN101006092B (zh) C型肝炎病毒rna依赖型rna聚合酶的抑制剂、以及使用该抑制剂的组合物和治疗剂
JP5147731B2 (ja) Ｈｃｖｎｓ５ｂ阻害剤
CN102056907B (zh) 杂环衍生物及其用途
AU2008276236B2 (en) Compounds and methods for modulating FXR
TW492971B (en) Nitrogen containing heteroaromtics as factor XA inhibitors
JP2010510191A (ja) 抗ウイルス剤としての２−カルボキシチオフェン誘導体
KR20070098914A (ko) 바이러스 감염을 치료하기 위한 인돌 유도체
WO2005014543A1 (ja) 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
CN107646036B (zh) 可用作5-脂氧合酶激活蛋白(flap)抑制剂的吡唑衍生物
JP3218045B2 (ja) 新規なチオフェン誘導体及びその医薬組成物
JP2006505625A (ja) Ｈｉｖ感染症を治療するためのピラゾールアミド
CN101980711B (zh) 芳族杂环稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
JP2008539181A (ja) Ｅｐ１受容体アンタゴニストとして有用なフラン化合物
KR20210129119A (ko) 파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물
JP2012532849A (ja) Ｃ型肝炎ｎｓ５ｂポリメラーゼの阻害剤としての１−（６員アゾ複素環式）−ピロリン−２−オン化合物、その医薬組成物、およびそれらの治療上の使用
JP2002322161A (ja) ビスヘテロ五員環化合物
HK1134676B (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
HK1134676A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
MX2008010043A (en) Hcv ns5b inhibitors
HK1109617B (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111005

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111212

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111222

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees